Latest Breaking News On - China based shenzhen kangtai biological products - Page 1 : comparemela.com
World Insights: Providing 500 mln vaccine doses to world, China aims to enhance int l cooperation against COVID-19 - China News
sina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com Daily Mail and Mail on Sunday newspapers.
World Insights: Providing 500 mln vaccine doses to world, China aims to enhance int l cooperation against COVID-19_GMW cn
en.gmw.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from en.gmw.cn Daily Mail and Mail on Sunday newspapers.
Malaysian firm aims to offer Chinese Covid-19 vaccine to private sector by September
thestar.com.my - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thestar.com.my Daily Mail and Mail on Sunday newspapers.
07 Jul 2021 / 13:21 H. Bernama
KUALA LUMPUR: Malaysian firm Yong Tai Bhd, which has partnered China-based Shenzhen Kangtai Biological Products Co. Ltd. (SZKT) to supply Chinese-produced Covid-19 vaccine in Malaysia, is targeting to offer its vaccines to private sector by September or October.
Yong Tai s chief executive officer Boo Kuang Loon said the group, which has an agreement with SZKT to supply 10 million doses per year with an additional option of 10 million if required, has commenced its trial vaccination.
“We are currently conducting the Phase III Clinical Trial in Malaysia and have made an application to the National Pharmaceutical Regulatory Agency for approval to use the vaccines here. If everything goes smooth, we aim to obtain the approval by September or October,“ he told Xinhua in a recent written interview.
2021-07-07 04:05:31 GMT2021-07-07 12:05:31(Beijing Time) Xinhua English
KUALA LUMPUR, July 7 (Xinhua) Malaysian firm Yong Tai Bhd, which has partnered China-based Shenzhen Kangtai Biological Products Co. Ltd. (SZKT) to supply Chinese-produced COVID-19 vaccine in Malaysia, is targeting to offer its vaccines to private sector by September or October.
Yong Tai s chief executive officer Boo Kuang Loon said the group, which has an agreement with SZKT to supply 10 million doses per year with an additional option of 10 million if required, has commenced its trial vaccination. We are currently conducting the Phase III Clinical Trial in Malaysia and have made an application to the National Pharmaceutical Regulatory Agency for approval to use the vaccines here. If everything goes smooth, we aim to obtain the approval by September or October, he told Xinhua in a recent written interview.